EcoDrugPlus

Mitogen-Activated Protein Kinase 3

Ensembl ID : ENSPCTG00005014316
Gene Symbol: MAPK3
3 Cross references
198 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 11

Ensembl ID : ENSPCTG00005018454
Gene Symbol: MAP3K11
1 Cross references
183 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 12

Ensembl ID : ENSPCTG00005020052
Gene Symbol: MAP3K12
1 Cross references
254 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 13

Ensembl ID : ENSPCTG00005008260
Gene Symbol: MAP3K13
1 Cross references
198 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 8

Ensembl ID : ENSPCTG00005003148
Gene Symbol: MAP3K8
3 Cross references
198 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 9

Ensembl ID : ENSPCTG00005003302
Gene Symbol: MAP3K9
1 Cross references
194 Possible Orthologues:

Monoamine Oxidase B

Ensembl ID : ENSPCTG00005020909
Gene Symbol: MAOB
3 Cross references
330 Possible Orthologues:

Motilin Receptor

Ensembl ID : ENSPCTG00005017145
Gene Symbol: MLNR
1 Cross references
165 Possible Orthologues:

Myeloperoxidase

Ensembl ID : ENSPCTG00005010486
Gene Symbol: MPO
3 Cross references
181 Possible Orthologues:

Natriuretic Peptide Receptor 2

Ensembl ID : ENSPCTG00005019560
Gene Symbol: NPR2
3 Cross references
259 Possible Orthologues:

Neuropeptide Y Receptor Y2

Ensembl ID : ENSPCTG00005000316
Gene Symbol: NPY2R
1 Cross references
246 Possible Orthologues:

Neurotensin Receptor 1

Ensembl ID : ENSPCTG00005010880
Gene Symbol: NTSR1
3 Cross references
211 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).